Fintel reports that on February 3, 2025, Redburn Atlantic upgraded their outlook for DexCom (NasdaqGS:DXCM) from Neutral to ...

IDEXX outlined its 2025 revenue target of $4.055 billion to $4.170 billion, reflecting organic growth of 6% to 9%. The CAG Diagnostic recurring revenue is expected to grow between 5% and 8% ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...